Design, synthesis and triglyceride-lowering activity of tricyclic matrine derivatives for the intervention of non-alcoholic fatty liver disease

Powell, 2021, Non-alcoholic fatty liver disease, Lancet, 10290, 2212, 10.1016/S0140-6736(20)32511-3 Heeren, 2021, Metabolic-associated fatty liver disease and lipoprotein metabolism, Mol. Metab., 50, 10.1016/j.molmet.2021.101238 Pafili, 2021, Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans, Mol. Metab., 256, e200194 Flessa, 2022, Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD/MAFLD). Pathophysiology of NASH in endocrine diseases, J. Cell. Biochem., 123, 1585, 10.1002/jcb.30247 Wiering, 2022, Treating inflammation to combat non-alcoholic fatty liver disease, J. Endocrinol., 256, e220194 Lee, 2023, An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease, J. Hepatol., 78, 1048, 10.1016/j.jhep.2023.01.024 Sheng, 2021, The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease, Lipids Health Dis., 20, 134, 10.1186/s12944-021-01561-2 Li, 2020, Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: bioactivities, structure-activity relationships and preliminary molecular mechanisms, Eur. J. Med. Chem., 188, 10.1016/j.ejmech.2019.111972 Li, 2023, Discovery and development of tricyclic matrinic derivatives as anti-diabetic candidates by AMPKα activation, Chin. Chem. Lett., 34 Tang, 2020, Structure-activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy, Eur. J. Med. Chem., 201, 10.1016/j.ejmech.2020.112315 Bechmann, 2012, The interaction of hepatic lipid and glucose metabolism in liver diseases, J. Hepatol., 56, 952, 10.1016/j.jhep.2011.08.025 Zhu, 2022, Effects of glucose metabolism, lipid metabolism, and glutamine metabolism on tumor microenvironment and clinical implications, Biomolecules, 12, 580, 10.3390/biom12040580 Wang, 2019, An integrated characterization of contractile, electrophysiological, and structural cardiotoxicity of Sophora tonkinensis Gapnep. in human pluripotent stem cell-derived cardiomyocytes, Stem Cell Res Ther, 10, 20, 10.1186/s13287-018-1126-4 Xu, 2022, Mitochondria targeting drugs for neurodegenerative diseases-design, mechanism and application, Acta Pharm. Sin. B, 12, 2778, 10.1016/j.apsb.2022.03.001 Jeena, 2019, Recent progress in mitochondria-targeted drug and drug-free agents for cancer therapy, Cancers (basel), 12, 4, 10.3390/cancers12010004 Bavlovič Piskáčková, 2021, Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity, Sci. Rep., 11, 4456, 10.1038/s41598-021-83688-x Ringstrand, 2011, The preparation of 3-substituted-1,5-dibromopentanes as precursors to heteracyclohexanes, Beilstein, J. Org. Chem., 7, 386 Dechandt, 2017, Triacsin C reduces lipid droplet formation and induces mitochondrial biogenesis in primary rat hepatocytes, J. Bioenerg. Biomembr., 49, 399, 10.1007/s10863-017-9725-9 Xu, 2022, Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor, Hepatology, 76, 1794, 10.1002/hep.32577 Flores-Costa, 2020, Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit, PNAS, 117, 28263, 10.1073/pnas.2000466117 Du, 2022, Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma, Acta Pharm. Sin. B, 12, 558, 10.1016/j.apsb.2021.09.019 Nakamura, 2013, Regulation of energy metabolism by long-chain fatty acids, Prog. Lipid Res., 53, 124, 10.1016/j.plipres.2013.12.001 Mana, 2021, High-fat diet-activated fatty acid oxidation mediates intestinal stemness and tumorigenicity, Cell Rep., 35, 10.1016/j.celrep.2021.109212 Honda, 2021, Structural basis for anti-non-alcoholic fatty liver disease and diabetic dyslipidemia drug saroglitazar as a PPAR α/γ dual agonist, Biol. Pharm. Bull., 44, 1210, 10.1248/bpb.b21-00232 Li, 2022, Bicyclol ameliorates advanced liver diseases in murine models via inhibiting the IL-6/STAT3 signaling pathway, Biomed. Pharmacother., 150, 10.1016/j.biopha.2022.113083